XL Therapeutics

Treatment of Conditions Caused by Deficiencies in WAS Protein Expression

Health Tech & Life Sciences
Non Active, May 2019 ceased to operate
Seed Ness Ziona, Israel Founded 2016
LinkedIn
Last updated 2026-06-18
Total raised
Last: 2017-05
Stage
Seed
Founded
2016
Headcount
1-10
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

XL Therapeutics is a biopharmaceutical company aiming to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, rare primary human immunodeficiencies caused by the absence or suboptimal function of the WAS protein (WASp), an adaptor protein expressed exclusively in hematopoietic cells and essential for normal hematopoietic cell function.

Funding history · 1 round · — total

2017-05
Undisclosed

Q&A

What is XL Therapeutics' primary focus?
XL Therapeutics is a biopharmaceutical company focused on developing small molecule compounds to treat Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, which are rare primary human immunodeficiencies.
When was XL Therapeutics founded?
XL Therapeutics was founded in May 2016.
What is the current status of XL Therapeutics?
XL Therapeutics is currently inactive, having ceased operations in May 2019.
Where is XL Therapeutics headquartered?
XL Therapeutics is headquartered in Ness Ziona, Israel.
Which investor participated in XL Therapeutics' funding round?
FutuRx participated in a funding round for XL Therapeutics in May 2017.
What is XL Therapeutics' employee count?
XL Therapeutics has an employee count in the 1-10 range.
Who are the founders of XL Therapeutics?
The founders of XL Therapeutics are Rachel Eran, who serves as CEO, and Mira Barda-Saad, who is the Inventor.
What is the product stage of XL Therapeutics?
XL Therapeutics' product is in the clinical trial stage.

Team · 2

Founder · CEO
Founder · Inventor

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B

Tags

medical-technologiesvascularpatientshospitalspharmaceuticalstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)